Drug intelligence / Profile preview

r-BHD

Development stage: Preclinical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

r-BHD is a novel biotin-DOTA conjugate developed for pretargeted antibody-guided radioimmunotherapy (PAGRIT) applications. This approach involves the sequential administration of an antibody, followed by a biotin-binding agent, and then the biotinylated radiolabeled conjugate. The DOTA component acts as a chelator for radioisotopes, enabling targeted delivery of radiation to disease sites. Preclinical and clinical results have been described for this conjugate.

Other names: reduced biotinamidohexylamine-DOTA

Beyond the preview

Go deeper on r-BHD.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on r-BHD.

Explore the full profile